Gyre Therapeutics, Inc. (GYRE) Reports Q2 EPS of $0.01

Gyre Therapeutics, Inc. (NASDAQ: GYRE) reported Q2 EPS of $0.01, versus $0.02 reported last year. Revenue for the quarter came in at $25.2 million, versus $29.33 million reported last year.

For earnings history and earnings-related data on Gyre Therapeutics, Inc. (GYRE) click here.

You May Also Be Interested In

• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• Citi cuts SK Hynix price target to KRW3,000,000 on FX pressure
• Citi raises Atlassian price target to $225, maintains Buy rating